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Two decades have passed since the discov-
ery of the first proteases that degrade the
amyloid β-protein (Aβ) (Roher et al., 1994;
Turner et al., 2004), the primary con-
stituent of the amyloid plaques that char-
acterize Alzheimer disease (AD) (Selkoe,
2000). While significant progress has been
made, this is an appropriate juncture to
reflect on what has been accomplished
and ask which research directions are most
likely to bear fruit going forward. Herein,
I argue that a renewed focus on intra-
cellular Aβ-degrading proteases (AβDPs)
is a highly promising direction for future
studies, one that is not only likely to
advance our understanding of the funda-
mental molecular pathogenesis of AD, but
also to critically inform the development
of effective therapies for use clinically.
To date, most studies of AβDPs have
focused predominantly on proteases that
act extracellularly (LaFerla et al., 2007;
Saido and Leissring, 2012; Leissring and
Turner, 2013). This is not surprising—
Aβ is, after all, a secreted peptide, and
amyloid plaques form extracellularly.
However, there is a growing body of evi-
dence implicating intracellular pools of Aβ
in the pathogenesis of AD (Saido and
Leissring, 2012; Leissring and Turner,
2013). Generally speaking, it has been
challenging to study specific pools of Aβ in
conventional animal models of AD, since
most models rely upon overexpression of
the β-amyloid precursor protein (APP),
which necessarily increases the levels of all
pools of Aβ simultaneously. The study of
AβDPs, by contrast, offers a unique win-
dow into the pathogenic role of Aβ, in no
small part because individual AβDPs have
unique subcellular localizations and pH
profiles, which can be exploited to selec-
tively target different pools of Aβ (e.g.,
extracellular, lysosomal, etc.) (Leissring
and Turner, 2013). This can be readily
achieved by overexpression, genetic dele-
tion or pharmacological manipulation
of appropriate AβDPs, either alone or in
tandem with APP overexpression.
There is a surprisingly long list of
reasons to focus particular attention on
intracellular AβDPs. First and foremost
is the fact that the production of Aβ
occurs intracellularly. Aβ is produced from
APP by the successive action of two pro-
teases, known as β-secretase—or β-site
APP cleaving protease 1 (BACE1)—and γ-
secretase, an intramembraneous complex
of four proteins, with presenilin-1 or -2
comprising the active site (De Strooper
et al., 2010). Of note, β- and γ-secretase
are both aspartyl proteases and, as such,
require an acidic environment to effect
their proteolytic activity (De Strooper
et al., 2010). As a consequence, although
there is some evidence for limited pro-
duction of Aβ at the cell surface (Chyung
et al., 2005), the vast majority of Aβ is
produced intracellularly, within acidified
compartments. From a therapeutic per-
spective, it is logical to study AβDPs that
are located closest to the sites of Aβ pro-
duction, as they are best positioned to
efficiently regulate Aβ levels, including Aβ
in the extracellular space.
Second, somewhat counter-intuitively,
the fraction of Aβ amenable to degra-
dation (i.e., non-aggregated) is primarily
located intracellularly, not extracellularly
as is widely assumed. In the human brain,
the extracellular space comprises ∼5% of
the total volume (Wyckoff and Young,
1956). By contrast, intracellular compart-
ments contiguous with the extracellular
space (e.g., ER, Golgi, endosomes, lyso-
somes, etc.) make up an estimated 17%
of total cell volume (Alberts et al., 2008).
Significantly, this figure ignores the many
other intracellular compartments where
Aβ has been detected (e.g., mitochon-
dria, cytosol). The reason this point is not
more widely appreciated may stem from
the fact that extracellular/intracellular vol-
ume ratio is dramatically reversed in
cultured cells—where, not coincidentally,
most known AβDPs were discovered and
many studies of Aβ metabolism were
performed.
Third, the fraction of Aβ present
in the extracellular space is to a large
degree bound to carrier proteins, notably
apolipoproteins E and J (ApoE, ApoJ) (Bu,
2009). When bound to ApoE or other
proteins, Aβ is protected from clearance
by AβDPs. Moreover, a principal func-
tion of these same molecules is, in fact,
to transport Aβ to intracellular sites for
degradation (Bu, 2009; Fuentealba et al.,
2010).
Fourth, intracellular Aβ is far more
prone to aggregation than extracellular
Aβ, because Aβ aggregation is dramatically
accelerated under acidic conditions (Su
and Chang, 2001). Not only is newly syn-
thesized Aβ produced within acidic com-
partments, but as mentioned, extracellular
Aβ is also transported to lysosomes by
ApoE and other Aβ-binding proteins (Bu,
2009). This point is key, because aggre-
gated Aβ is far less amenable to clearance
by proteolytic degradation or other means.
In addition to the preceding, largely
theoretical, arguments for focusing on
intracellular Aβ degradation, there is a
compelling body of empirical evidence
that is supportive, as well. In animal stud-
ies, overexpression or genetic deletion of
extracellular AβDPs have had the expected
effects on cerebral Aβ levels and amyloid
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plaques (Saido and Leissring, 2012). For
instance, recombinant neprilysin (Park
et al., 2013), administered either directly to
brain or via peripheral administration by
way of a brain-targeting domain (Spencer
et al., 2014), not only lowered brain Aβ
levels, but also ameliorated the learning
and memory deficits present in APP trans-
genic mice. Similarly, neuronal overex-
pression of neprilysin in APP transgenic
mice, achieved via peripheral administra-
tion of an adeno-associated viral vector
designed to target neurons, achieved sim-
ilar results (Iwata et al., 2013). However,
the full complement of favorable bio-
chemical and behavioral outcomes of the
latter studies have not been uniformly
observed. For example, one highly notable
study (Meilandt et al., 2009) investigated
a transgenic mouse model with high-level
overexpression of neprilysin (Leissring
et al., 2003). While neprilysin overex-
pression was found to markedly reduce
extracellular Aβ levels and, in fact, to
completely eliminate all amyloid plaque
formation in a robust APP transgenic
mouse model (Mucke et al., 2000), levels
of oligomeric forms of Aβ—an especially
neurotoxic species strongly implicated in
the AD pathogenesis—were found to be
unchanged in these animals (Meilandt
et al., 2009). Crucially, neprilysin over-
expression failed to mitigate the learning
and memory defects present in the AD
mouse model used in this study (Meilandt
et al., 2009). The marked difference in the
outcomes of these aforementioned stud-
ies does not have a ready explanation, but
may be attributable to the different forms
of neprilysin examined (i.e., soluble vs.
membrane-bound), to the extent of over-
expression achieved, or to the particular
animal model employed. Nevertheless, the
latter study does demonstrate that it is
possible to completely eliminate all extra-
cellular amyloid deposition, while hav-
ing no effect on learning and memory
and while leaving intact a critical pool of
intracellular Aβ.
Conversely, emerging evidence suggests
that selective manipulation of intracellular
AβDPs can yield the hoped-for effects on
behavioral outcomes. For instance, phar-
macological enhancement of lysosomal
Aβ degradation was found to effectively
reverse the defects in cognitive perfor-
mance as well as synaptic composition
present in two AD mouse models (Butler
et al., 2011). Notably, the enhancement
of lysosomal degradation also resulted in
a lowering of extracellular Aβ deposition
(Butler et al., 2011).
Results such as these imply that the
extracellular pool of Aβ may be much
less consequential than has been widely
assumed. As radical as it may sound,
these findings suggest that extracellular Aβ
deposition may in fact constitute a some-
what of an “epiphenomenon” obscur-
ing more material events going on at
intracellular sites (Leissring and Turner,
2013). This conclusion is bolstered by
other experimental paradigms, particu-
larly studies of the effects of overexpressing
Aβ alone within different subcellular com-
partments. For example, expression of Aβ
exclusively in the extracellular space led
to amyloid plaque formation (McGowan
et al., 2005; Kim et al., 2013), as expected,
but resulted in no significant effects on
learning and memory (Kim et al., 2013).
In marked contrast, overexpression of Aβ
in the cytosol has been shown to be pro-
foundly toxic in cultured cells (Zhang
et al., 2002) and, in vivo, resulted in pro-
found neurodegeneration (LaFerla et al.,
1995)—a feature that is notably absent
from many other animal models of AD.
The possible pathogenic role of
intracellular Aβ—and, indeed, its very
existence—has been a subject of contro-
versy for several decades (LaFerla et al.,
2007). A large number of studies have
identified Aβ within non-canonical com-
partments, including the cytosol and
mitochondria (LaFerla et al., 2007). But
evaluating the veracity of these claims
has been complicated by the difficulty
in reliably detecting the relatively small
amounts of putative intracellular Aβ—
particularly against a background of
abundant Aβ present extracellularly and
within the endolysosomal pathway and
other canonical intracellular compart-
ments. Nevertheless, in my opinion, the
evidence supporting the idea that intra-
cellular Aβmay be particularly pathogenic
is sufficiently compelling to merit further
investigation.
The study of intracellular AβDPs may
be an effective way to finally resolve
the controversy surrounding both the
existence of and the pathogenic role
of intracellular Aβ. By virtue of their
distinctive subcellular localizations and
pH optima, AβDPs constitute pow-
erful tools for manipulating different
pools of Aβ and, thereby, gaining fresh
insight into their potential involvement
in the pathogenesis of AD (Leissring and
Turner, 2013). AβDPs are present in a
diverse range of subcellular compart-
ments: insulin-degrading enzyme (IDE) in
cytosol (Roth, 2004), IDE and presequence
peptidase inmitochondria (Leissring et al.,
2004; Falkevall et al., 2006), BACE-2 and
endothelin-converting enzymes 1- and -2
in endosomes (Eckman et al., 2001; Abdul-
Hay et al., 2012), and in cathepsins B and
D in lysosomes (Gan et al., 2004; Leissring
et al., 2009) (see Saido and Leissring, 2012;
Leissring and Turner, 2013 for compre-
hensive reviews). Collectively, these AβDPs
represent a diverse set of experimental
tools for selectively manipulating differ-
ent pools of Aβ. Because AβDPs degrade
other substrates and also subserve differ-
ent physiological functions, studies based
on them cannot be expected to constitute
perfectly “clean” tests of the importance of
different pools of Aβ. Nevertheless, com-
parison of the consequences of genetic
deletion and/or overexpression of spa-
tially distinctive AβDPs is virtually certain
to offer additional insight into the roles
that different pools of intracellular Aβ do
or do not play in AD pathogenesis. To
the extent possible, comparative studies
of this type would ideally be conducted
within the same animal model and utilize
the same behavioral and biochemical out-
comes. Additionally, the use of an animal
model that harbors human tau might help
to elucidate the mechanistic link between
Aβ accumulation and tauopathy, one of
the most important unresolved questions
in AD research.
In conclusion, there is a compelling
theoretical and empirical rationale for
the field to undertake a renewed focus
on intracellular AβDPs. The knowledge
we can expect to derive from the study
of extracellular AβDPs appears to be, at
best, approaching an asymptote and, at
worst, revealing that extracellular pools of
Aβ may not be involved in the patho-
genesis of AD to the extent so widely
assumed for so long. The study of intra-
cellular AβDPs, by contrast, seems poised
to yield insights into questions that are
not merely academic or theoretic, but
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highly practical—for example, the rela-
tive merits of immunotherapies, which
only target extracellular Aβ, versus secre-
tase inhibitors or modulators, which affect
intracellular Aβ as well. Considering the
growing interpersonal, financial and soci-
etal impact of AD, and the current lack
of therapies, it is wise to pursue any
and all avenues that may lead to effective
treatments, and the study of intracellu-
lar AβDPs seems an especially promising
direction for future investigation.
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